Printer Friendly

MEDCO RESEARCH'S ADENOCARD APPROVED IN CANADA

 LOS ANGELES, May 13 /PRNewswire/ -- Medco Research, Inc. (AMEX: MRE) today announced that the Health Protection Branch (HPB) has granted marketing approval of Adenocard(R) in Canada for the treatment of paroxysmal supraventricular tachycardia (PSVT), a condition characterized by an abnormally rapid heart rate.
 Medco expects Adenocard to be launched in Canada in the third quarter 1993 at a price comparable to that in the United States. This will represent the first introduction of Medco's adenosine product to the Canadian market. The company's Adenoscan(R) product, used in the diagnosis of coronary artery disease, has already been approved in Canada, but is not yet available for sale.
 Adenocard has been marketed in the United States since December 1989 by Fujisawa USA, Inc. (Fujisawa). Sales in 1992 were approximately $20 million and are expected to remain strong, particularly since Adenocard was adopted last year as the drug-of-choice for PSVT by the American Heart Association guidelines for Advanced Cardiac Life Support.
 Since 1985 Medco has licensed the U.S. and Canadian manufacturing and marketing rights to Adenocard to Fujisawa. Although Medco and Fujisawa are in litigation concerning the research and development agreement for Adenoscan, Medco has no reason to believe, and does not expect, that such proceedings will have any effect on Fujisawa's marketing and sales of Adenocard.
 Medco Research is a pharmaceutical company engaged in the acquisition, research and development of new prescription drugs for the diagnosis or treatment of certain cardiovascular diseases and cancer.
 -0- 5/13/93
 /CONTACT: Archie W. Prestayko of Medco Research, Inc., 213-966-4148, or Frederic J. Spar of Kekst and Company, 212-593-2655, for Medco Research, Inc./
 (MRE)


CO: Medco Research, Inc. ST: California IN: MTC SU:

CK-OS -- NY026 -- 7998 05/13/93 10:07 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 13, 1993
Words:289
Previous Article:LASERMEDICS EXPECTS TO FILE WITH FDA BY EARLY FALL
Next Article:READING & BATES CORPORATION ACQUIRES SHARES OF ARCADE DRILLING AS
Topics:


Related Articles
FUJISAWA USA. INC. FILES DECLARATION JUDGEMENT ACTION AGAINST MEDCO RESEARCH INC.
MEDCO RESEARCH REPORTS FIRST QUARTER FINANCIAL RESULTS
MEDCO RESEARCH'S ADENOCARD DRUG IS APPROVED FOR MARKETING IN SEVEN EUROPEAN COUNTRIES
MEDCO RESEARCH GAINS FDA APPROVAL OF ITS NEW PRE-FILLED SYRINGE FORMULATION OF ADENOCARD
MEDCO RESEARCH REPORTS FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
MEDCO RESEARCH AND REPLIGEN AGREE TO MERGE; COMPANIES TO COMBINE PRODUCT PORTFOLIOS AND OTHER RESOURCES
MEDCO RESEARCH REPORTS SECOND-QUARTER RESULTS
MEDCO RESEARCH APPOINTS ROGER BLEVINS PRESIDENT
MEDCO RESEARCH REPORTS THIRD-QUARTER RESULTS
Fujisawa Healthcare to Increase Capacity to Manufacture Adenoscan(R) And Adenocard(R).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters